TY  - GEN
AU  - Holkova,Beata
AU  - Kmieciak,Maciej
AU  - Bose,Prithviraj
AU  - Yazbeck,Victor Y
AU  - Barr,Paul M
AU  - Tombes,Mary Beth
AU  - Shrader,Ellen
AU  - Weir-Wiggins,Caryn
AU  - Rollins,April D
AU  - Cebula,Erin M
AU  - Pierce,Emily
AU  - Herr,Megan
AU  - Sankala,Heidi
AU  - Hogan,Kevin T
AU  - Wan,Wen
AU  - Feng,Changyong
AU  - Peterson,Derick R
AU  - Fisher,Richard I
AU  - Grant,Steven
AU  - Friedberg,Jonathan W
TI  - Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas
SN  - 1029-2403
PY  - 2016///1213
KW  - Adult
KW  - Aged
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - adverse effects
KW  - Biomarkers
KW  - Combined Modality Therapy
KW  - Cytokines
KW  - blood
KW  - Drug Monitoring
KW  - Drug Resistance, Neoplasm
KW  - Female
KW  - Humans
KW  - Hydroxamic Acids
KW  - administration & dosage
KW  - Lymphoma, B-Cell
KW  - Male
KW  - Middle Aged
KW  - Neoplasm Recurrence, Local
KW  - Oligopeptides
KW  - Retreatment
KW  - Treatment Outcome
KW  - Vorinostat
N1  - Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.3109/10428194.2015.1075019
ER  -